Definitive Healthcare (NASDAQ:DH) Stock Price Up 7.2% – What’s Next?

Definitive Healthcare Corp. (NASDAQ:DH)’s stock price rose 7.2% during mid-day trading on Monday . The stock traded as high as $5.50 and last traded at $5.52. Approximately 67,575 shares traded hands during mid-day trading, a decline of 91% from the average daily volume of 724,288 shares. The stock had previously closed at $5.15.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on DH shares. Barclays restated an “underweight” rating and issued a $4.00 target price on shares of Definitive Healthcare in a research note on Monday, January 13th. Needham & Company LLC reissued a “hold” rating on shares of Definitive Healthcare in a research report on Thursday, January 16th. Finally, Stephens began coverage on shares of Definitive Healthcare in a report on Friday, December 20th. They set an “equal weight” rating and a $5.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $5.72.

Definitive Healthcare Stock Down 0.9 %

The firm has a fifty day moving average price of $4.48 and a two-hundred day moving average price of $4.40. The company has a current ratio of 2.49, a quick ratio of 2.49 and a debt-to-equity ratio of 0.33.

Insider Activity at Definitive Healthcare

In other Definitive Healthcare news, insider William Moschella sold 45,000 shares of Definitive Healthcare stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $4.70, for a total value of $211,500.00. Following the completion of the sale, the insider now owns 433,830 shares of the company’s stock, valued at approximately $2,039,001. This trade represents a 9.40 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 14.84% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Definitive Healthcare

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Massachusetts Financial Services Co. MA grew its stake in shares of Definitive Healthcare by 36.8% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 6,053,233 shares of the company’s stock valued at $27,058,000 after purchasing an additional 1,626,813 shares during the period. State Street Corp boosted its holdings in shares of Definitive Healthcare by 29.4% in the third quarter. State Street Corp now owns 1,399,729 shares of the company’s stock worth $6,257,000 after buying an additional 317,952 shares during the last quarter. 272 Capital LP grew its position in Definitive Healthcare by 74.8% during the third quarter. 272 Capital LP now owns 1,114,080 shares of the company’s stock valued at $4,980,000 after buying an additional 476,766 shares during the period. New York State Common Retirement Fund increased its holdings in Definitive Healthcare by 3.2% during the fourth quarter. New York State Common Retirement Fund now owns 771,792 shares of the company’s stock valued at $3,172,000 after buying an additional 23,815 shares during the last quarter. Finally, Victory Capital Management Inc. raised its position in Definitive Healthcare by 6.5% in the third quarter. Victory Capital Management Inc. now owns 542,170 shares of the company’s stock worth $2,424,000 after acquiring an additional 33,161 shares during the period. Hedge funds and other institutional investors own 98.67% of the company’s stock.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.